International conference on "Statistical issues in pharmaceutical development ; collaboration between Europe and the USA ; regulation of medicines from research to marketing". Leicester, GBR, 1996/07/16.
This paper deals with a conceptual discussion of a variety of statistical concepts, methods and strategies that are relevant to the quantitative assessment of risk derived from safety data collected during the pre-and post-marketing phase of a new drug's life cycle.
A call is made for the use of more standard approaches to the analysis of safety data that are statistically and epidemiologically rigorous and for attempts to link the strategies for pre-market safety assessment with strategies for post-market safety evaluation.
This link may be facilitated by recognizing the limitations and complementary roles played by pre-and post-market safety data collection schemes and by linking the quantitative analyses utilized for either exploratory or confirmatory purposes of risk assessment in each phase of safety data collection.
Examples are provided of studies specifically designed to evaluate risk in a post approval setting and several available guidelines intended to improve the quality of these studies are discussed.
Mots-clés Pascal : Analyse risque, Pharmacovigilance, Epidémiologie, Analyse statistique, Analyse quantitative, Autorisation mise sur marché, Commercialisation, Analyse donnée
Mots-clés Pascal anglais : Risk analysis, Pharmacovigilance, Epidemiology, Statistical analysis, Quantitative analysis, Marketing authorization, Marketing, Data analysis
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 98-0446001
Code Inist : 002B02A06. Création : 25/01/1999.